Resumo

ARELLANO BARRIGA, Guillermo Vinicio et al. Antiangiogenic drugs in neovascular retinal diseases. Rev Cient Cienc Méd [online]. 2017, vol.20, n.1, pp.31-37. ISSN 1817-7433.

An Increased vascular endothelial growth factor in degenerative, obstructive and even neoplastic processes is the main pathophysiological mechanism for the formation of aberrant blood vessels, which are detrimental and put at risk the visual acuity of the individual. In recent years, the creation of antiangiogenic (anti-VEGF) drugs and their intravitreal use have revolutionized the therapy of retinal neovascular diseases and have provided an increase in the quality of life of people suffering from it. The following narrative review article seeks to analyze the safety, efficacy, posology, route of administration and international regimens of anti-VEGF treatment in Exudative Age-Associated Macular Degeneration (AMD), Diabetic Macular Oedema (DME), Occlusion of the Central Retina Vein (CRVO), Retinal Venous Branch Occlusion (BRVO) and Retinoblastoma. The anti-VEGF intraocular therapy represents a safe and effective choice in the treatment of retinal neovascular pathologies.

Palavras-chave : AntiVEGF; Retinoblastoma; Neovascular.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )